




MEDISCA® NETWORK INC.  
TECHNICAL SUPPORT SERVICES  
FORMULATION CHEMISTRY DEPARTMENT  
TOLL-FREE: 866-333-7811  
TELEPHONE: 514-905-5096  
FAX: 514-905-5097  
[technicalservices@medisca.net](mailto:technicalservices@medisca.net)

9/10/2008; page 1  
TMP 045

Suggested Formula	Bumetanide 0.5 mg/mL Intravenous Injection (Solution, 10 mL)	FIN	F 000 608v3
-------------------	--------------------------------------------------------------	-----	-------------

### SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Bumetanide 0.5% Stock Solution †	1.00	mL				
Edetate Disodium, USP	0.001	g				
Citric Acid (Anhydrous), USP	0.01	g				
Sodium Citrate (Dihydrate), USP	0.02	g				
Sodium Chloride, USP	0.06	g				
Benzyl Alcohol, NF	0.10	mL				
Sterile Water For Injection, USP	8.0	mL				
Sterile Water For Injection, USP	q.s. to 10.0	mL				
Sodium Hydroxide 1N Solution	As required					
† <b>Bumetanide 0.5% Stock Solution</b>						
Bumetanide, USP	0.100	g				
Alcohol, USP	20.0	mL				





Suggested Formula	Bumetanide 0.5 mg/mL Intravenous Injection (Solution, 10 mL)	FIN	F 000 608v3
-------------------	--------------------------------------------------------------	-----	-------------

## SPECIAL PREPARATORY CONSIDERATIONS

### Ingredient-Specific Information

<i>Light sensitive (protect from light whenever possible):</i>	<i>Bumetanide</i> <i>Benzyl Alcohol</i>
<i>Hygroscopic (protect from moisture whenever possible):</i>	<i>Edetate Disodium</i>

### Suggested Preparatory Guidelines

Non-Sterile Preparation     Sterile Preparation

Processing Error / Testing Considerations: To account for processing error, pH testing, sterility and endotoxin testing considerations during preparation, it is suggested to measure an additional **20 to 25%** of the required quantities of ingredients.

Special Instruction: This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797*. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Bumetanide 0.5 mg/mL Intravenous Injection (Solution, 10 mL)	FIN	F 000 608v3
-------------------	--------------------------------------------------------------	-----	-------------

### SUGGESTED PREPARATION (for 10 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): ____	Processing Error	Qty. to measure
Bumetanide 0.5% Stock Solution § †	1.00	mL			
Edetate Disodium, USP §	0.001	g			
Citric Acid (Anhydrous), USP §	0.01	g			
Sodium Citrate (Dihydrate), USP §	0.02	g			
Sodium Chloride, USP §	0.06	g			
Benzyl Alcohol, NF §	0.10	mL			
Sterile Water For Injection, USP §	8.0	mL			
Sterile Water For Injection, USP §	q.s. to 10.0	mL			
Sodium Hydroxide 1N Solution §	As required				
<b>† Bumetanide 0.5% Stock Solution</b>					
Bumetanide, USP §	0.100	g	---	---	
Alcohol, USP §	20.0	mL	---	---	

\* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.



Suggested Formula	Bumetanide 0.5 mg/mL Intravenous Injection (Solution, 10 mL)	FIN	F 000 608v3
-------------------	--------------------------------------------------------------	-----	-------------

Preparatory Instruction


**IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique**

1.	<p><b><u>Equipment sterilization:</u></b></p> <p>Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.</p>
2.	<p><b><u>Bumetanide 0.5% Stock Solution preparation:</u></b></p> <p>A. Add 0.100 g of Bumetanide to 20.0 mL of Alcohol and continuously mix until all solid particles have completely dissolved.</p>
3.	<p><b><u>Powder preparation:</u></b></p> <p>A. Combine and triturate the following ingredients together to form a fine homogeneous powder blend:</p> <ul style="list-style-type: none"> <li>- Edetate Disodium</li> <li>- Citric Acid (Anhydrous)</li> <li>- Sodium Citrate (Dihydrate)</li> <li>- Sodium Chloride</li> </ul>
4.	<p><b><u>Liquid preparation:</u></b></p> <p>A. Combine and mix the following ingredients together until homogeneously dispersed:</p> <ul style="list-style-type: none"> <li>- Sterile Water For Injection (8.0 mL plus processing error adjustments)</li> <li>- Bumetanide 0.5% Stock Solution (1.00 mL plus processing error adjustments)</li> <li>- Benzyl Alcohol</li> </ul> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>
5.	<p><b><u>Powder to liquid integration:</u></b></p> <p>A. Incrementally add the fine homogeneous powder (Step 3A) to the homogeneous liquid-like dispersion (Step 4A).</p> <p><u>Specification:</u> Continuously mix.</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>
6.	<p><b><u>pH testing:</u></b></p> <p>A. Draw an appropriate amount of the mixture (Step 5A).</p> <p>B. Test the pH of the sample. It should lie between 7.1 and 7.8.</p> <p>C. <u>If the pH &lt; 7.1, carefully add in a dropwise manner the Sodium Hydroxide 1N Solution to the mixture:</u></p> <ol style="list-style-type: none"> <li>1. Draw and transfer 1 or 2 drops of the Sodium Hydroxide 1N Solution to the mixture.</li> <li>2. Stir for at least 5 minutes to evenly disperse the Sodium Hydroxide 1N Solution.</li> <li>3. Re-test the pH.</li> <li>4. Continue to add the Sodium Hydroxide 1N Solution until the pH of 7.1 to 7.8 is obtained.</li> </ol> <p>IMPORTANT: Do not allow the pH to rise above 7.8..</p> <p>D. Continuously mix until all solid particles have completely dissolved.</p>



Suggested Formula	Bumetanide 0.5 mg/mL Intravenous Injection (Solution, 10 mL)	FIN	F 000 608v3
-------------------	--------------------------------------------------------------	-----	-------------

7.	<p><b><u>Filling to volume:</u></b></p> <p>A. Add additional Sterile Water For Injection to the above solution to fill to the required batch size (10.0 mL plus processing error adjustments).</p> <p><b><u>Specifications:</u></b> Continuously mix.</p> <p><b><u>End result:</u></b> Homogeneous liquid-like solution.</p>
8.	<p><b><u>Filtering and transferring:</u></b></p> <p>Aseptically filter the solution through a 0.22-<math>\mu</math>m sterile filter into the recommended dispensing container (see Packaging requirements). Transfer the remainder into a separate dispensing container. This is to be used as the Test sample for sterility and endotoxin testing.</p>
9.	<p><b><u>Filter integrity test:</u></b></p> <p>Validate filter integrity by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.</p>
10.	<p><b><u>Sterility testing:</u></b></p> <p>Validate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory guidelines.</p>





Suggested Formula	Bumetanide 0.5 mg/mL Intravenous Injection (Solution, 10 mL)	FIN	F 000 608v3
-------------------	--------------------------------------------------------------	-----	-------------

### SUGGESTED PRESENTATION

Estimated Beyond-Use Date	14 days, refrigerated		Packaging Requirements	Sterile, light-resistant, unit-dose injection vials.
	BUD based on a successful sterility and endotoxin test result.			
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	6	Protect from light.
	2	Keep out of reach of children.	7	Keep refrigerated. Do not freeze.
	3	Discard container after use.	8	Equilibrate to room temperature before use.
	4	Discard in the presence of particulate matter.	9	<b>Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.</b>
	5	Do not use if discolored.		
Pharmacist Instructions	Add any auxiliary labels specific to the active ingredient to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions.			

### REFERENCES

1.	Tonicity, Osmoticity, Osmolality and Osmolarity. In: Gennaro AR, ed. <i>Remington: The Science and Practice of Pharmacy, 20th Edition</i> . Baltimore, MD: Lippincott Williams & Wilkins; 2000: 246.
2.	USP <797> Pharmaceutical Compounding – Sterile Preparations. US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXVIII / National Formulary 23</i> . Rockville, MD. 2004: 2461.
3.	Buffered and Isotonic Solutions. In: Martin A. <i>Physical Pharmacy, Fourth Edition</i> . Philadelphia, PA: Lippincott Williams & Wilkins; 1993:169-89.
4.	Bumetanide (Monograph). In: O'Neil MJ. <i>The Merck Index 13<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 249.
5.	Bumetanide. In: <i>Physicians Desk Reference</i> ®. Montvale, NJ: Thomson PDR;2005: 2214.
6.	Bumetanide (Monograph). US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXV / National Formulary 20</i> . Rockville, MD; 2001: 256.
7.	Bumetanide. US Pharmacopeial Convention, Inc. <i>USP DI – Drug Information for the Health Care Professional</i> . Rockville, MD: US Pharmacopeial Convention, Inc; 1990: 1214.

**DISCLAIMER: MEDISCA NETWORK INC. & RÉSEAU MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAVE PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.**